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Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and devastating lung disorder of unknown origin, with very poor
prognosis and no effective treatment. The disease is characterized by abnormal activation of alveolar epithelial cells,
which secrete numerous mediators involved in the expansion of the fibroblast population, its differentiation to
myofibroblasts, and in the exaggerated accumulation of extracellular matrix provoking the loss of lung architecture.
Among the excessively produced mediators are several matrix metalloproteases (MMPs) which may contribute to
modify the lung microenvironment by various mechanisms. Thus, these enzymes can not only degrade all the
components of the extracellular matrix, but they are also able to release, cleave and activate a wide range of
growth factors, cytokines, chemokines and cell surface receptors affecting numerous cell functions including
adhesion, proliferation, differentiation, recruiting and transmigration, and apoptosis. Therefore, dysregulated
expression of MMPs may have profound impact on the biopathological mechanisms implicated in the
development of IPF. This review focuses on the current and emerging evidence regarding the role of MMPs
on the fibrotic processes in IPF as well as in mouse models of lung fibrosis.
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Background
Idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF), the most aggressive fi-
brotic lung disorder, is a chronic, progressive, irreversible,
and usually lethal lung disease of unknown etiology [1, 2].
IPF is an aging-associated disease usually found in
people over 50 and its incidence and prevalence in-
creases markedly in the elderly. Although the underlying
mechanisms linking aging with IPF are not fully under-
stood, it has been hypothesized that IPF patients may
have an accelerated process of lung aging, characterized
by increased genomic instability, abnormal shortening of
telomeres, epithelial cell senescence, mitochondrial dys-
function, and loss of proteostasis, among others [3, 4].
However, how these mechanisms of aging interrelate is
currently largely unknown. In this context, it has been
proposed that IPF is the consequence of the convergence
of three conditions, a genetic architecture that results in
an easy loss of the alveolar epithelial integrity, “acceler-
ated” aging, and a distinctive epigenetic “profibrotic”
modification [4, 5]. This “mechanistic convergence
model” hypothesizes that IPF is driven by the co-
incidence of multifactorial components which results in
a distinct pathogenic cascade leading to the aberrant ac-
tivation of alveolar epithelial cells [1, 4, 6]. This notion is
supported by the presence of increasing numbers of
phenotypically varied epithelial cells which are excep-
tionally active, and synthesize nearly all the mediators
that contribute to the formation and activation of the fi-
broblastic foci and to the progressive and exaggerated
accumulation of extracellular matrix. Among these, vari-
ous MMPs have been found dysregulated and evidence
indicates that play a central role not only in the abnor-
mal tissue remodeling but also influencing the epithelial
and mesenchymal cell behavior [7] Table 1.
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Table 1 Matrix metalloproteinases in pulmonary fibrosis
MMP IPF Murine fibrosis model In vitro related studies References
MMP1
Collagenase 1
↑Plasma ↑Serum ↑ BAL ↑ Lung
Expressed by AECs and AM
No data in Mmp1a mouse (McolA) Bidirectional correlation with HIF1α in AECs,
represses mitochondrial oxygen consumption




Expressed by BECs, AECs, fibroblasts
and fibrocytes.
Not done in Mmp2 null mice - [27, 46, 63]
MMP3
Stromelysin 1
↑ Serum ↑ BAL ↑Lung




Induces epithelial-mesenchymal transition [35–37, 48, 70]
MMP7
Matrilysin
↑Plasma ↑Serum ↑BAL ↑Lung
Expressed by BECs and AECs
Mmp7-null mice protected from
bleo fibrosis






Expressed by blood monocytes, AM, BECs,
AECs and fibrocytes
↑ LungMmp8-null mice protected
from bleo fibrosis








with WT in bleo fibrosis
MMP9-over-expression in AM
reduces fibrosis
Expressed by Thy-1(−) lung
fibroblasts with TGF-β1; enhances
fibroblasts migration
[7, 39, 40, 42, 46, 48]
MMP10
Stromelysin 2
↑ Serum ↑ BAL
Expressed by AM, BECs and AECs
↑ Lung




a Not done in Mmp11-null mice -
MMP12
Macrophage elastase
↑ BAL ↑ Lung
Mmp12-null mice no changes with





Expressed by AM, BECs and AECs
↑ Lung
Mmp13-null mice increased bleo






Expressed by AECs, AM and endothelial cells.
↑ Lung
Deficient mice die between
20 and 90 days after birth




Expressed by endothelial and AECs
No data. - [63]
MMP16
MT3-MMP
Expressed by fibroblasts and AECs No data Upregulated in fibroblasts by TGF-β1 [63]
MMP17
MT4-MMP
a No data -
MMP19 ↑ Upregulated in hyperplastic AECs ↑ Lung
Mmp19-null mice increased bleo
fibrosis
Positive correlation with COX2 in AECs.












Table 1 Matrix metalloproteinases in pulmonary fibrosis (Continued)
MMP20
Enamelysin
a Not done in Mmp20-null mice -
MMP21 a No data. -
MMP23B a Not done in Mmp23- null mice -
MMP24
MT5-MMP
Expressed by basal BECs, and in areas of
squamous metaplasia




Cell type localization unknown.
No data - [7]
MMP26
Matrilysin-2
a Absent in mouse -
MMP27 a No data. -
MMP28
Epilysin
↑Lung Mmp28-null mice reduced
bleo fibrosis
Protects BECs and AECs from
apoptosis
[7, 64, 75]
a the expression of these MMPs has not been found altered in IPF vs normal lungs by microarrays
BECs bronchiolar epithelial cells
AM alveolar macrophages
BAL bronchiolar lavage












MMPs, the zinc-dependent matrixins belong to the
M10A subfamily of metallopeptidases, and have long
been considered as the principal effectors of extracellular
matrix (ECM)/core matrisome proteins degradation. The
contribution of MMPs to the matrisome remodeling is
vastly complex since these endopeptidases have a broad
scope of influence. They are not only responsible for
ECM degradation, but also shed cell membrane proteins,
and process and cleave diverse bioactive mediators such
as growth factors, cytokines and chemokines, considered
as matrix associated proteins, modulating their activity
either by direct cleavage, or releasing them from extra-
cellular matrix bound stocks [8, 9].
In humans the MMP family consist of 24 genes in-
cluding two genes for MMP23 and in mice, in which the
experimental models of pulmonary fibrosis are mainly
performed, MMPs comprise 23 genes. In mice, human
MMP1 gene (collagenase 1) is represented by Mmp1a
and Mmp1b genes, they have only one Mmp23 gene,
and lack MMP26 (matrilysin-2) gene [10].
Numerous studies have shown that MMPs are strongly
regulated at multiple levels, starting from transcriptional
regulation of gene expression through growth factors,
cytokines, hormones, and cell-extracellular matrix, and
cell-cell interactions. Post-transcriptional regulatory pro-
cesses include mRNA stability, protein translational effi-
ciency, and regulation by microRNAs. After translation,
zymogen activation of different MMPs may take place
intracellularly, at the cell surface, or in the extracellular
space. Then, the activity of MMPs is inhibited by different
mechanisms and molecules, such as the TIMP family of
proteins (TIMPs), α2-macroglobulin, and the membrane-
associated RECK (reversion-inducing Cys-rich protein
with Kazal motifs) [11, 12].
Most of the MMPs are secreted enzymes, although
there are also membrane type MMPs (MT-MMPs),
and even some MMPs have been reported in intra-
cellular organelles, including nuclear localization act-
ing on intracellular substrates, or as transcription
factors [13–18].
Under normal conditions, their activity is low but in-
creases during repair or remodeling processes and in sev-
eral pathological conditions. Traditionally, as MMPs have
been considered mainly as proteases involved in the deg-
radation of ECM proteins, it has been hypothesized that
pathologic fibrotic scars represent an improper balance
between deposition (excessive) and degradation (deficient)
of ECM components.
However, the finding that some MMPs are highly
expressed in a complex fibrotic disease such as IPF
seemed to contradict this postulate and numerous evi-
dence suggest that this simplistic concept is not only in-
sufficient but furthermore, probably wrong.
In this review, key pathophysiological roles for MMPs
in IPF will be discussed herein paying special attention
to those that have been shown to be upregulated, which
have known correlations with profibrotic or anti-fibrotic
mediators, and have mechanistic information through
experimental models or in vitro studies to understand
their participation in the pathogenesis of the disease
(Fig. 1).
MMP7 a profibrotic mediator
MMP7 is one of the molecules most highly expressed in
IPF when compared with normal lungs or lung tissues
from other interstitial lung diseases and is localized pri-
marily in the aberrantly activated alveolar epithelial cells
(AECs) and in bronchiolar epithelial cells [19, 20].
It has been postulated that MMP7 plays a profibrotic
role based on the finding that MMP7 deficient mice are
protected from bleomycin induced lung fibrosis. Its pro-
fibrotic role might be multiple considering its broad sub-
strate specificity that includes basement membrane and
ECM components. Additionally, MMP7 processes nu-
merous bioactive substrates including FAS ligand (FasL),
β4 integrin, E-cadherin, plasminogen, transmembrane
tumor necrosis factor α (pro-TNF-α), syndecan, insulin
growth factor binding protein-3 (IGFBP-3) among others
[21]. Interestingly, in the AECs of IPF lungs MMP7 co-
localizes with osteopontin a multifunctional cytokine in-
volved in cell adhesion and migration suggesting that
this interaction may have an important effect on IPF
[22]. This hypothesis is supported by the finding that
MMP7 is induced and activated by osteopontin while
the latter is cleaved and activated by MMP7 [23]. Add-
itionally, osteopontin increases the expression of type 1
collagen and TIMP1 and decreases MMP1 on lung fi-
broblasts supporting the notion that this bidirectional
regulation between MMP7 and osteopontin plays a pro-
fibrotic role in IPF.
MMP19 an antifibrotic mediator
The evaluation of the transcriptional signature of hyper-
plastic epithelial cells compared with conserved epithelial
cells in the same lungs revealed that MMP19 is highly up-
regulated in hyperplastic epithelial cells adjacent to fi-
brotic regions [24]. Interestingly, MMP19 overexpression
displayed a positive correlation with prostaglandin-
endoperoxide synthase 2 (PTGS2; COX2), which was also
upregulated in hyperplastic alveolar epithelial cells and co-
localized with MMP19 [24].
Surprisingly, Mmp19 deficient mice displayed an exag-
gerated lung fibrotic response to bleomycin compared
with WT mice suggesting that MMP19 plays a protective
role [24]. Interestingly, COX-2 has been also suggested as
protective against pulmonary fibrogenesis [25]. Therefore,
it can be hypothesized that the increased expression of
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MMP19 and COX-2 in the hyperplastic epithelial cells
represents a normal but potentially insufficient response
to continuous epithelial injury/activation in IPF lungs.
Supporting an antifibrotic role of MMP19, lung fibro-
blasts lacking this enzyme exhibit dysregulation of several
profibrotic pathways and show a substantial increase in
proliferation and transmigration [26]. These results sug-
gest that, in lung fibroblasts, MMP19 has strong regula-
tory effects on the synthesis of key ECM components,
supporting the finding of a stronger fibrotic response ob-
served in the lungs from MMP19 deficient mice.
The paradox of MMP1 overexpression in IPF
Transcriptional and immunohistochemical analyses have
consistently revealed that MMP1 is significantly overex-
pressed in IPF lungs compared with controls [7, 27].
This represented an intriguingly finding since MMP1
is an enzyme capable of cleaving fibrillar collagens, the
typical excessively accumulated ECM molecules in IPF.
Furthermore, MMP1 is associated with pathologies char-
acterized by excessive ECM degradation, such as
rheumatoid arthritis and lung emphysema [28–31].
A partial explanation for this paradox is that in IPF
lungs, MMP1 is localized primarily in the reactive
alveolar epithelium while is virtually absent in fibroblasts
in the interstitial compartment where collagens are be-
ing accumulated.
Transfection of MMP1 in alveolar epithelial cells indi-
cates that this enzyme induces cell proliferation, acceler-
ates wound closing and protects cells from apoptosis
[32]. Importantly, MMP1 was identified in the mito-
chondria of AECs and repressed mitochondrial respir-
ation, induced the expression of hypoxia-inducible
factor-1α (HIF-1α) under normoxic conditions, and de-
creased the production of both mitochondrial and total
reactive oxygen species (ROS) [32]. Moreover, MMP1
was also up regulated when HIF-1α was induced by hyp-
oxia in AECs suggesting a bidirectional cross talk.
Altogether, these data suggest a complex role of MMP1
in IPF, which goes far beyond of digesting fibrillar
collagens.
Mmpla, the putative murine orthologue of MMP1
shows low identity (58 % in amino acids) [33], and does
not seem to play a similar role in mice as MMP1 in
humans [34]. It is expressed less ubiquitously in healthy
Fig. 1 Putative roles of some MMPs in pulmonary fibrosis. In activated alveolar epithelial cells, MMP-7 cleaves osteopontin and potentiates its
function which in turn upregulates and activates MMP-7. In this profibrotic cross-talk, osteopontin upregulates the expression of ECM proteins.
MMP-19 co-localizes and co-regulates with COX2 which end product, prostaglandin E2, is a potent suppressor of fibroblast proliferation and
collagen production. Deficiency of MMP-19 in fibroblasts results in the upregulation of several profibrotic genes and pathways that provoke an
increase of fibroblast migration and proliferation and a decrease of these processes in epithelial cells. Upregulation of MMP-1 in alveolar epithelial
cells represses mitochondrial respiration and oxidative stress, while promotes cell proliferation, migration, and HIF-1α expression, and induces an
anti-apoptotic phenotype. MMP3 induces EMT, and MMP9 is upregulated by TGF β in Thy-1 negative fibroblasts which in turn activates this
growth factor. OPN = osteopontin; COX2 = cyclooxygenase 2; ECM = extracellular matrix; EMT = epithelial to mesenchymal transition
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mouse tissue than in humans and their expression seems
to be restricted exclusively to reproductive tissues since it
was found only in the placenta and in the testes, while in
humans plays a more fundamental role in tissue remodel-
ing processes. Importantly, it is absent in the embryo,
lung, kidney, brain, heart, muscle, and liver [33, 34]. In
this context, the classical approach of using Mmp1a defi-
cient mice as a tool to explore the participation of MMP1
in experimental pulmonary fibrosis would be far from be-
ing informative.
MMP3 may contribute to epithelial-mesenchymal transition
It has been found that MMP3 is upregulated in IPF lungs
as well as in bleomycin induced lung fibrosis [35–37].
Moreover, Mmp3-null mice were protected from
bleomycin-lung injury [35]. Furthermore, transient adeno-
viral vector-mediated expression of recombinant MMP3
in rat lungs resulted in accumulation of myofibroblasts
and fibrosis. MMP3 is expressed by diverse cell types in
IPF lungs, including bronchioalveolar epithelial cells, al-
veolar macrophages, and fibroblasts [35]. Interestingly,
treatment of lung epithelial cells with MMP3 resulted in
activation of the β-catenin signaling pathway with the sub-
sequent induction of several β-catenin-target genes and of
epithelial-mesenchymal transition [35]. These findings
suggest that MMP3 may be mechanistically involved in
the pathogenesis of IPF through the induction of epithelial
to mesenchymal transition.
Expression of MMP9 is associated with the absence of Thy-1
receptor in lung fibroblasts
MMP9 is also increased in IPF lungs where it is expressed
by alveolar epithelial cells, macrophages, neutrophils and
fibroblasts in fibroblastic foci [27]. The finding that lung
fibroblasts in this disease synthesize MMP9 is intriguing
since these cells do not express this enzyme in vitro, but a
finding in our laboratory opened some light to this result.
Thy-1, a glycophosphatidylinositol-linked glycoprotein, is
expressed by most fibroblasts from normal lungs while
IPF fibroblasts are usually Thy-1 negative. Actually, loss of
Thy-1 expression in fibroblasts correlates with regions of
active fibrogenesis [38]. Recently, it was demonstrated that
Thy-1(−) lung fibroblasts stimulated with TGF-β1
expressed MMP9, through activation of ERK1/2 signaling
pathway, while Thy-1 (+) cells did not [39]. Moreover,
treatment of Thy-1(−) fibroblasts with β-glycan, a TGF-β
receptor antagonist, abolished MMP9 induction. These
findings suggest that in the microenvironment of IPF
lungs fibroblasts/myofibroblasts, which do not express
Thy-1, when stimulated by the epithelial-produced TGF-
β1 synthesize MMP9. Importantly, among many effects,
MMP9 is also able to activate TGF-β1 contributing to en-
hance the pool of active TGF-β1 [40]. Therefore, TGF-β
induction of MMP9 in Thy-1 (−) fibroblasts could be part
of a fibrogenic feedback loop in IPF lungs.
In contrast, results in experimental models have given
some puzzling results. MMP9 is usually found elevated
in lung tissue homogenates and bronchoalveolar lavage
fluids obtained from bleomycin-treated mice. Interest-
ingly, the absence of this enzyme did not seem to influ-
ence the severity of fibrosis after intratracheal bleomycin
[41]. However, the presence of hypertrophied and hyper-
plastic cuboidal epithelial cells, a usual epithelial change
occurring in regions of alveolar injury, was observed in
Mmp-9 (+/+) but hardly found in the Mmp-9 deficient
mice. The reason of this finding is unknown but it can
be speculated that MMP9 may facilitate distal airway
epithelial cells to migrate into sites of alveolar injury. By
contrast, transgenic overexpression of human MMP9 in
macrophages attenuates lung fibrosis [42].
Role of MMPs in the traffic of fibrocytes to the IPF lungs
Fibrocytes are bone marrow derived cells characterized
by the expression of fibroblast and leukocyte markers.
They circulate in peripheral blood and appear to be a
source of fibroblasts/myofibroblasts that participate in
the mechanisms of wound healing and tissue fibrosis
[43]. The percentage of circulating fibrocytes is signifi-
cantly increased in patients with IPF, mainly in those
suffering an acute exacerbation [44]. It has been pro-
posed that the main mechanism of fibrocyte homing to
the lungs is the CCL12/CXCR4 axis [45]. Lately, it was
found that fibrocytes strongly express several MMPs
including MMP2, MMP9, MMP8 and MMP7 [46]. Im-
portantly, MMP8, MMP2 and MMP9 seem to partici-
pate in the process of tissue migration and homing since
the movement of fibrocytes through collagen I is highly
associated with the expression of collagenase MMP8
while its transmigration through basement membrane-
like proteins is associated to MMP2 and MMP9 [46].
Therefore, the synthesis of these enzymes may facilitate
the transendothelial and tissue migration of fibrocytes
and also contribute in the remodeling of ECM during
the development of IPF.
MMP8 may contribute to the inflammatory response in
experimental lung fibrosis
Some studies have shown that MMP-8 levels are ele-
vated in plasma, lung homogenates and BAL fluids from
IPF patients [47–50]. Also, it has been reported that
Mmp8 increases in the lungs of mice early after bleo-
mycin treatment remaining elevated until 21 days [51].
In a long-term study, the expression of this enzyme was
increased at the inflammatory phase, stayed up until
8 weeks post-bleomycin (the peak of fibrosis) then de-
creasing during fibrosis resolution [37].
Pardo et al. Respiratory Research  (2016) 17:23 Page 6 of 10
In the experimental model, this enzyme may enhance
inflammation and inflammatory-driven fibrosis cleaving
IL10, MIP-1a and Cxcl10, and actually, Mmp8-null mice
are protected from bleomycin-induced lung fibrosis al-
though the molecular mechanisms are yet unclear [52].
Supporting a role in inflammatory disorders that evolve
to fibrosis we have demonstrated that MMP8 together
with MMP9 associated with neutrophils were increased
in hypersensitivity pneumonitis and correlated with the
development of lung fibrosis [53]. However, its role in
the pathogenesis in IPF is uncertain.
MMP13 is deregulated but its role is uncertain
MMP13 one of the enzymes able to cleave fibrillar colla-
gens has recently been reported to be increased at
mRNA and protein level in IPF. It was mainly localized
in alveolar and bronchiolar epithelial cells, and in alveo-
lar macrophages [54]. Its role in lung fibrosis experimen-
tal models is uncertain and results obtained so far are
conflicting. Thus, it has been shown that Mmp13
deficient mice are more susceptible to bleomycin-
induced lung fibrosis while appear to be protected from
radiation-induced pulmonary fibrosis [54, 55]. Moreover,
no difference in the fibrotic response was observed after
hyperoxic lung injury, although Mmp13 deficient mice
displayed an increased inflammatory reaction [56]. The
reasons for this discrepancy and its possible role of
MMP13 in the pathogenesis of IPF are largely unknown.
Contribution of the bleomycin model to our understanding
of the role of MMPs in lung fibrogenesis
Substantial amount of information regarding the patho-
genesis of lung fibrosis come from different animal
models where integrative genomic and proteomic have
identified several dysregulated MMPs involved in the
fibrotic response. Importantly however, bleomycin-
induced fibrosis, the most used experimental model, as
well as any model of pulmonary fibrosis described so far,
does not mimic the pathobiology of IPF, but shares some
of the fibrogenic mechanisms thus contributing to our
understanding of the human disease.
Following we summarize the findings reported with
some other MMPs evaluated in experimental models of
lung fibrosis with scarce data in IPF.
Mmp12
Mmp12 is one of the most upregulated genes in lungs
from bleomycin-treated mice. However, the putative effect
on the inflammatory and fibrotic responses has given
contradictory results. Thus, while some studies shown
that Mmp12-deficiency had no effect on bleomycin-
induced inflammation/fibrosis, others reported that
MMP12 has a profibrotic role, since Mmp12-null mice
have decreased collagen accumulation after several
injuries including bleomycin, and anti-Fas antibody
[57–59]. Mechanistically, it has been suggested that
MMP12 plays an important role in TGF-β1 signaling
pathway activation.
Mmp14
Several findings indicate that Mmp14 is upregulated in
experimental lung fibrosis [36, 37, 60]. MMP14 is a
membrane bound enzyme known also known as MT1-
MMP that although does not have the classical domain
structure of collagenases has been documented as a true
collagenase able to degrade collagen fibers [61]. More-
over, it has been shown that MT1-MMP was the sole
proteolytic effector of the invasive activity required by
human and mice fibroblasts during trafficking through
type-I collagen-riche 3-D barriers [62]. We have found
that in IPF lungs that MMP14 was the most highly
expressed of the membrane type MMPs and was
expressed by alveolar epithelial cells, however its role in
this disease is presently unknown [63].
Mmp28
MMP28 is the last member of the mammalian MMP
family and we found that it is upregulated in IPF lungs
[7]. However, studies dealing with its possible implica-
tion in the pathogenesis of lung fibrosis are scanty. A
recent report indicates that Mmp28-null mice are pro-
tected from bleomycin-induced lung fibrosis because
this deficiency results in higher macrophage influx to
the lungs compared with WT mice, and an impaired
M1/M2 polarization [64].
MMPs as prognostic biomarkers in IPF patients
IPF patients display different clinical phenotypes includ-
ing slowly and rapid progressive clinical courses, and oc-
casional abrupt deterioration due to acute exacerbations.
In this context, to predict outcome is very difficult and
the development of blood biomarkers may help to iden-
tify patients at risk for accelerated disease progression
and ideally those who will benefit from therapy.
The search for a peripheral blood protein signature for
IPF has suggested that several MMPs could potentially
fulfill this role.
In a pioneer study it was revealed that high concentra-
tions of MMP7 and MMP1, together, are sufficient to
distinguish IPF patients from patients with COPD,
hypersensitivity pneumonitis, sarcoidosis and healthy
controls [47]. These results were corroborated in an in-
dependent validation cohort including patients with IPF
and familial pulmonary fibrosis showing additionally that
MMP7 concentrations correlated with the severity of the
disease. These findings have been verified by several
studies, which demonstrate that levels of circulating
MMP7 predict progression and outcome where higher
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concentrations of this enzyme negatively correlated with
pulmonary function tests and survival. More recently, it
has been suggested that blood levels of MMP7 may also
help to the differential diagnosis between IPF and other
fibrotic lung disorders [65, 66]. The mechanisms by
which the expression of MMP7 gene and protein in-
creases in IPF is unclear, but may be at least partially re-
lated to lower DNA methylation [67]. Also, significant
associations between rs11568818AA and rs11568819CT
genotypes and elevated plasma levels of MMP7 have
been identified. Interestingly, the G-to-A transition of
rs11568818 resulted in a novel-binding site for the fork-
head box A2 (FOXA2) transcription factor that seems to
increase sensitivity of the polymorphic MMP7 promoter
to FOXA2 [68]. Therefore, both epigenetic and genetic
mechanisms may provide the bases for the upregulation
of MMP7 in IPF.
Likewise, the increase of MMP1 may be related to the
presence of the 2G/2G genotype at −1,607, which is asso-
ciated with increased gene expression [69]. Additionally,
the sequencing of the MMP1 promoter have revealed a
putative gene-environment interaction between the T/G
SNP at position −755 and smoking in this disease [69].
This is an important finding because several studies per-
formed in sporadic and familial cases of IPF have shown
that smoking is a strong risk factor of IPF [1].
Other MMPs may also be useful to predict outcome
but the studies performed so far have been done in small
cohorts of IPF patients and without an independent val-
idation. For example, it was observed that an increase in
serum MMP3 or MMP10 correlated to disease severity
and shortened survival time [70, 71].
Elevated BALF levels of MMP3, 7, 8 and 9 have been
reported in rapid compared with slow progressive IPF
patients [48]. In a recent study higher concentrations of
MMP8 in plasma and BALF levels were corroborated;
however, these levels do not correlate with mortality or
decline in lung function and it was suggested that this
enzyme may not be a prognostic biomarker [50]. Import-
antly however, most of the IPF patients in the IPF cohort
had a history of cigarette smoking while most of the
control subjects were non-smokers. Therefore, it cannot
be ruled out that higher MMP-8 levels could be associ-
ated with the smoking status [50].
Circulating peptides naturally produced by MMPs deg-
radation have been also identified in IPF and proposed as
an alternative in the search of informative biomarkers.
Using this approach, a recent study demonstrated that
changes with time in the concentrations of collagen 1 de-
graded by MMP2/9/13, collagen 3 degraded by MMP9,
collagen 6 degraded by MMP2/9, MMP-degraded bigly-
can, ADAMTS-degraded collagen 3, and MMP-degraded
C-reactive protein, strongly correlate with outcome, both
progression and survival [72]. These findings were
confirmed in a validation cohort of IPF patients and age-
matched and sex-matched healthy controls suggesting
that IPF progression and outcome can be determined
through detection of temporal change in the concentra-
tions of MMPs degraded circulating proteins having the
potential to become theragnostic biomarkers [72].
Conclusions
In the last two decades, MMPs have emerged as critical
players in the pathogenesis of lung fibrosis. However,
their participation is not only restricted to their role as
ECM modulators, but also determining cell behavior.
Crucially, some MMPs seem to promote a fibrotic re-
sponse while others appear to play a protecting role. In
this context, it is important to emphasize that there use
as therapeutic targets have to be certain of which spe-
cific MMP we want to tackle. Earlier efforts to block
MMP activity in cancer patients have failed to achieve
clinical success [73]. One of the reasons is that there are
structural similarities in the catalytic domain of MMPs
and the failed phase III clinical trials have used broad-
spectrum small-molecule MMP inhibitors that likely
inhibited most of them. Importantly, MMPs may have
beneficial and detrimental effects, and in the last years,
it has become clear that some individual MMPs such as
MMP7 contribute to progression and poor outcome of
IPF while others such as MMP19 seems to be protective.
Thus, putative inhibitors will need to be highly selective
for a particular MMP and able to accumulate in the
fibrotic lung without eliciting adverse systemic effects.
Moreover, lung remodeling in IPF is a dynamic bio-
pathological process and it is unknown whether the
activities of MMPs vary during the course of the disease.
Finally, because some functions of MMPs involve non-
catalytic domains and even occur in intra-cellular
locations, novel protein-binding drugs are needed. Our
knowledge of the role of MMPs is still scanty, and fur-
ther research is needed to develop selective agents as
therapeutic targets
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